Bio-Rad Laboratories/$BIO
1D1W1MYTD1Y5YMAX
Capital at risk
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
- Ticker
- $BIO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,450
- Headquarters
- Hercules, United States
- Website
- www.bio-rad.com
BIO Metrics
BasicAdvanced
$10B
46.32
$8.26
1.05
-
Price and volume
Market cap
$10B
Beta
1.05
52-week high
$396.23
52-week low
$236.73
Average daily volume
256K
Financial strength
Current ratio
3.142
Quick ratio
2.153
Long term debt to equity
0.13
Total debt to equity
0.191
Interest coverage (TTM)
5.58%
Profitability
EBITDA (TTM)
441
Gross margin (TTM)
52.04%
Net profit margin (TTM)
8.59%
Operating margin (TTM)
10.52%
Effective tax rate (TTM)
36.53%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
1.66%
Return on equity (TTM)
3.11%
Valuation
Price to earnings (TTM)
46.323
Price to revenue (TTM)
3.975
Price to book
1.41
Price to tangible book (TTM)
1.57
Price to free cash flow (TTM)
29.151
Free cash flow yield (TTM)
3.43%
Free cash flow per share (TTM)
13.118
Growth
Revenue change (TTM)
1.37%
Earnings per share change (TTM)
-28.16%
3-year revenue growth (CAGR)
-2.21%
10-year revenue growth (CAGR)
2.47%
3-year earnings per share growth (CAGR)
-17.07%
10-year earnings per share growth (CAGR)
9.61%
What the Analysts think about BIO
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
Analyst projections of the future price of Bio-Rad Laboratories stock.
Bulls say / Bears say
Digital PCR is showing strong product momentum despite the Life Science downturn, with Q2 instrument revenue growing more than 20% year over year. (Bio-Rad)
Clinical Diagnostics provides relative resilience: Q2 segment revenue increased 2.6% reported and 0.3% on a currency-neutral basis, led by quality systems, diabetes, and blood-typing products. (SEC)
Life Science remains the key drag: Q2 2026 segment revenue fell 5.1% on a currency-neutral basis, primarily because of continued weakness in academic research demand. (Bio-Rad)
Management’s full-year outlook still allows for currency-neutral revenue to decline as much as 3.0%, while Q2 non-GAAP operating income fell to $81.1 million from $88.6 million year over year. (Bio-Rad)
Earnings and equity value remain materially exposed to Bio-Rad’s Sartorius holding: Q2 net income was substantially boosted by fair-value gains, while the company identifies risks from Sartorius share-price movements and broader biopharma-sector volatility. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
BIO Financial Performance
Revenues and expenses
BIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
BIO News
AllArticlesVideos
Funds containing BIO
AllUSDEURGBP
Fund name | Fund size | $BIO weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.80% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.80% |
iShares Healthcare Innovation£DRDR | £1B | 0.80% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.20% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.